drugset / Trial / NCT04219254
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Timeline
- Start
- 2020-06-29
- Primary completion
- 2027-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI-1206 | Monoclonal antibody | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |